The FDA has expanded approval for Moderna's RSV vaccine to include younger adults at risk, pending national immunization schedule recommendations. mRESVIA is the first non-Covid-19 mRNA vaccine in the US, now available for ages 18-59 alongside 60+.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing